
Immuneering Investor Relations Material
Latest events

Study Result
Immuneering
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Immuneering Corporation
Access all reports
Immuneering Corporation is a clinical-stage oncology company focused on developing novel therapeutics for cancer patients. The company leverages bioinformatics and computational biology to design drugs that cyclically disrupt core oncogenic signaling pathways, such as the MAPK pathway, with the aim of reducing tumor growth while minimizing toxicity. Immuneering’s pipeline includes its lead product candidate, IMM-1-104, a dual-MEK inhibitor in clinical trials targeting cancers caused by mutations in RAS and/or RAF. Another notable candidate is IMM-6-415, also targeting solid tumors. The company emphasizes a disease-agnostic approach, aiming to address cancers with high unmet medical needs through insights derived from its translational bioinformatics platform. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Immuneering Corporation


Study Result
Immuneering Corporation


Study Result
Immuneering Corporation
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
IMRX
Country
🇺🇸 United States